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Abstract
Our goal is an office-based, handheld ultrasound system to target, detach, break, and/or expel 
stones and stone fragments from the urinary collecting system to facilitate natural clearance. 
Repositioning of stones in humans (maximum 2.5 MPa, and 3-second bursts) and breaking of 
stones in a porcine model (maximum 50 cycles, 20 Hz repetition, 30 minutes, and 7 MPa peak 
negative pressure) have been demonstrated using the same 350-kHz probe. Repositioning in 
humans was conducted during surgery with a ureteroscope in the kidney to film stone movement. 
Independent video review confirmed stone movements (≥ 3 mm) in 15 of 16 kidneys (94%). No 
serious or unanticipated adverse events were reported. Experiments of burst wave lithotripsy 
(BWL) effectiveness on breaking human stones implanted in the porcine bladder and kidney 
demonstrated fragmentation of 8 of 8 stones on post mortem dissection. A 1-week survival study 
with the BWL exposures and 10 specific-pathogen-free pigs, showed all findings were within 
normal limits on clinical pathology, hematology, and urinalysis. These results demonstrate that 
repositioning of stones with ultrasonic propulsion and breaking of stones with BWL are safe and 
effective.
1. INTRODUCTION
Stone disease management has changed little in 30 years, and patient care, technology, and 
cost can be improved.1 Patients endure pain and anxiety in waiting for spontaneous stone 
passage. The Urologic Diseases in America project found 65% of kidney stone patients 
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filled an opioid prescription and 40% utilized the emergency department (ED) each year 
including 10% who used the ED more than once to deal with their pain while waiting for 
definitive management.2 That management includes ionizing radiation for monitoring even 
asymptomatic stones, with 70% of stone patients receiving imaging each year, and the 
majority of these receiving more than one scan. Treatment is not always definitive, and 30% 
of surgeries need to be repeated.2 The inefficiencies of ED care, repeat imaging and repeat 
surgeries make urinary stone disease the costliest non-malignant urologic disease,2 and the 
annual cost of care of a stone patient is twice that of patients without stone disease.3 The 
ability to noninvasively break stones and expel the fragments in the outpatient setting has the 
potential to reduce risk, reduce cost, and improve care. This paper is an update on the 
progress by our NIH Program Project and collaborators to develop and validate an office-
based system to find, break, and expel stones and stone fragments from the urinary 
collecting system to facilitate natural clearance. As such this presentation in the Special 
Session “Biomedical Acoustics and Physical Acoustics: Shock Waves and Ultrasound for 
Calculus Fragmentation” established the status in the path to initial clinical implementation, 
and other papers4–9 in the session reported progress and approaches to solve technical 




Figure 1 shows photos of the University of Washington system called Propulse 1. The 
operator places the probe on the skin, visualizes the stone with ultrasound (US) imaging and 
then applies the therapy by a footswitch without interrupting real time US imaging. Propulse 
1 uses an SC-50 probe (50 mm diameter) for stone repositioning and an SC-60 (60 mm 
diameter) probe for stone repositioning and breaking.10 There is an investigational device 
exemption (IDE) for human trials of stone repositioning with Propulse 1 and either probe. A 
second IDE application has been submitted to FDA to add the outputs to break stones. 
Repositioning is called ultrasonic propulsion and has a maximum of 3 s bursts at 50% duty 
cycle of up to 2.4 MPa peak negative pressure, to up to 10 minutes. Stone breaking is called 
Burst Wave Lithotripsy (BWL)11 and in the IDE application is limited to 20 cycle pulses at 
17 Hz for up to 10 minutes at 6 MPa (the maximum attainable with the system and probe) 
PNP. However, safety tests reported here were performed with a slightly different system 
which enabled testing at higher pressure levels (30 minutes, 24 cycles, 10 Hz, and 7 MPa 
PNP).
B. HUMAN STUDIES OF ULTRASONIC PROPULSION
There are four studies discussed, all being conducted under one IDE, to measure feasibility 
of repositioning stones. Subjects are assessed for inclusion and exclusion criteria and go 
through the process of informed consent. They are screened by ultrasound to confirm the 
stone can be seen. If the subjects are awake, they respond to a visual analog pain score 
before and after screening and the investigational procedure. All subjects are contacted once 
per week for 4 weeks following for stone passage or adverse events. All receive imaging 
follow-up after 6 weeks and a chart review at 90 days.
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C. PRECLINICAL STUDIES OF BWL
A 7-day survival study follows the protocol used twice before in our previous ultrasonic 
propulsion applications.10,12 Clinical simulation of BWL was conducted by delivering 
transcutaneous exposures to intact kidneys without stones. Safety assessments included 
drawing and analyzing blood and urine before and following the investigational procedure 
and just prior to necropsy 1 week later. A full necropsy was performed and analyzed by a 
board-certified veterinary pathologist. The studies were conducted following good 
laboratory practice (GLP) guidelines.
The effectiveness of Propulse 1 was tested in clinical simulation by fragmenting and 
repositioning stones that were surgically implanted in each bladder of 3 pigs and in the 
kidney of one of these pigs.
3. RESULTS
A. HUMAN STUDIES OF ULTRASONIC PROPULSION
Table 1 shows a summary of the four human studies. Ultrasonic propulsion has been used 
safely 65 times on subjects. Ultrasonic propulsion has successfully repositioned stones and 
clinical benefits have been observed. Studies continue.
B. PRECLINICAL STUDIES OF BWL
Table 2 shows the preclinical results of safety and effectiveness of BWL in animals. The 
survival study showed no injury to the maximum proposed exposure (7 MPa, 10 Hz 
repetition rate, 20 cycles, 30 minutes, 350 kHz). Since the exposure time, acoustic pressure 
and beam width bound our application, we feel these studies demonstrate that our proposed 
outputs are safe for the proposed human studies. In the effectiveness study, stones were all 
broken completely in under 10 minutes of exposure. Some pigs were given a total exposure 
up to 25 minutes, and in no case was gross injury observed. These results are consistent with 
the results presented by Wang et al.8 of this session and in review by the Journal of 
Endourology.14
All treatments were monitored with US imaging, and the corresponding video was recorded. 
In no cases was echogenicity away from the stone seen, which would imply a need to pause 
the treatment to avoid injury and shielding by a cavitation cloud. May et al. previously 
showed detection of echogenicity for > 20 s correlated 100% with injury.15 In addition, the 
bladder fragmentation was readily observed in real time, and all three stones appeared to 
fragment completely within 3 minutes. In the kidney and bladder, BWL pulses enhanced the 
brightness of the Doppler twinkling artifact on the US image of the stone. In the kidney, 
fragmentation was not as observable during BWL because the stone and pieces filled a calyx 
and did not move, but fragmentation was made obvious on the Propulse 1 ultrasound image 
by separating the fragments with one pulse of ultrasonic propulsion. Video screen shots 
during breaking and repositioning were presented in the talk and can be viewed through the 
hyperlinks; twinkling artifact on the left of the screen highlights the stone in green color,16 
B-mode is on the right, and controls are on the lower half. Additional videos are available at 
apl.uw.edu/pushingstones.
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We report work toward an office-based, handheld ultrasound device to target, detach, break, 
and reposition stones and stone fragments in the urinary space to facilitate natural clearance. 
We have developed systems for imaging, breaking, and repositioning stones. Repositioning 
of stones has been safe and effective in humans. Breaking of stones with specific burst wave 
lithotripsy parameters is safe and effective in animal studies, and these data have been 
submitted in an application for an investigational device exemption for human trials.
In addition, our research group has developed the tools and approaches to continue to refine, 
expand, and test use of an integrated device. Specifically, we are working to develop 
advanced acoustic feedback (e.g., cavitation feedback15) and an understanding of how to use 
that feedback to adjust treatment parameters to enhance effectiveness of treatment without 
compromising safety. For instance, the stones targeted here were within the beam width of 
our probe, and it may be desirable to break larger stones. Fortunately, there remains 
considerable room to to continue to improve effectiveness and expand the application. For 
example, Tamaddoni and Hall,17 in this session described a technology to control cavitation, 
and Zwaschka et al.18 showed addition of weak ultrasonic propulsion pulses to BWL 
accelerated the comminution rate threefold.
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Photographs of the University of Washington integrated stone imaging, breaking, and 
repositioning system. The inset with the handheld probe shows the rectangular imaging 
transducer surrounded by the circular therapy transducer.
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• therapy and imaging with Philips HDI C5–2 transducer
• 13 of 15 were awake subjects
• subjects with de novo stones, residual fragments, pre-surgery and during surgery.
Key Results
• moved stones in 14 of 15 subjects
• depths up to 11 cm, stones as large as 10 mm
• relieved obstruction pain 1 of 1
• 4 of 6 past surgery passed fragments
• 4 large stones on clinical image were revealed to be passable fragment piles




15 of 19 




Independent confirmation of movement of stones by imaging with a camera in the kidney.
Materials and Methods
• Stones were repositioned by ultrasonic propulsion with a handheld probe against the skin 
while observing with the ureteroscope during surgery.
• Ultrasound and URS videos were sent to independent reviewers blinded to the exposure 
conditions to score movement greater than 3 mm, which was determined as a clearly 
resolvable displacement.
Key Results
• Independently confirmed motion >3mm in 15 of 16 kidneys
• The video quality was too poor in the 16th case to make a determination.
• Twice obviated the need for a basket to reposition stones
• No serious or unanticipated adverse events.
• Skin reddening (3), skin bruising (1), and skin irritation (1) were considered related to 
the propulsion procedure.
• hematuria, nausea, changes in voiding and bowel habits, and pain/discomfort, considered 
related to URS and not ultrasonic propulsion.
symptomatic 




4 of 20 subjects 
complete
Purpose
Move a symptomatic stone in the ureter with the goal of moving a small stone into the bladder or a 
large stone back into the kidney to relieve pain.
Materials and Methods
• Subjects with a symptomatic stone in the ureteropelvic junction (UPJ) or ureterovesical 
junction (UVJ) are recruited in the ED.
• Movement and hydronephrosis are assessed from US images before and after by a 
radiologist blinded to the exposure conditions.
• No treatment is withheld from the subjects.
Initial Results
• Moved 1 of 2 UPJ stones >3mm to a new location back toward the kidney.
• Moved 1 of 2 UVJ stones < 3mm and same patient (1 of 2) passed the stone within 24 
hours.
• No devic- related adverse events.
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21 of 60 
complete (13 of 
30 treatment 
arm and 8 of 30 
control arm)
Purpose
Test clinical benefit of expelling residual fragments
Materials and Methods
• Subjects with residual fragments remaining >1 month after surgery.
• Subjects are followed every 6 months for 3 years for recurrence.
Initial Results
• 13 of 30 recruited in the treatment arm
• 8 of 30 recruited in in the control arm
• (Also de novo stones in 1 subject were repositioned; the subject passed the stone that 
evening and more the next day.)
• Early interim results reported to NIH and FDA are encouraging but are not reported here 
because they are interim.
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Assess for acute and long term effects of clinical treatment
Materials and Methods
• 10 animals including 6 treatment and 4 controls
• All groups split evenly between male and female
• 1 treatment site in either left (n = 2) or right (n = 4) kidney
• Dose: 30 min treatments at 350 kHz transmit frequency, 24 cycle pulse duration, 10 Hz PRF, 
and 7 MPa PNP
Key Results
• No significant histological changes to the kidney or other potentially intervening tissues
• All blood chemistry, hematology, and urine values were within the expected normal limits 
for outbred swine







Test the ability to break stones with the proposed clinical system and dose in a porcine model
Materials and Methods
• 7 stones (4–7 mm) implanted across 3 bladders and 1 stone in 1 kidney
• 10–25 min treatments at 350 kHz transmit frequency, 20 cycle pulse duration, 17 Hz PRF, 
and 6 MPa PNP
Key Results
• No fragment recovered > 2 mm in 8 of 8 cases
• No gross injury observed
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